PerkinElmer has received the CE Mark for its reverse transcription polymerase chain reaction (RT-PCR) newborn screening assay.
The company's Eonis test screens for spinal muscular atrophy, severe combined immunodeficiency, and X-linked agammaglobulinemia in newborns and will be integrated into PerkinElmer's sample-to-result workflow.